A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer

Prostate

Volumn 69, Issue 9, 2009, Pages 928-937

  Locke, Jennifer A ^a   Fazli, Ladan ^a   Adomat, Hans ^a   Smyl, Jil ^a   Weins, Kristin ^a   Lubik, Amy A ^a,b   Hales, Dale B ^c   Nelson, Colleen C ^a,b   Gleave, Martin E ^a   Tomlinson Guns, Emma S ^a,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c UNIVERSITY OF ILLINOIS   (United States)

^d VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

CYP17A1; Exosomes; Prostate cancer; Serum

Indexed keywords

CYTOCHROME B5; CYTOCHROME P450 17; CYTOCHROME P450 REDUCTASE;

ARTICLE; CANCER GROWTH; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; EXOSOME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADRENAL CORTEX NEOPLASMS; ANDROGENS; CELL COMMUNICATION; CELL LINE, TUMOR; CELL POLARITY; CHOLESTEROL; DISEASE PROGRESSION; ENZYME ACTIVATION; EXOSOMES; HUMANS; KIDNEY; MALE; MICROSOMES, LIVER; NADPH-FERRIHEMOPROTEIN REDUCTASE; ORCHIECTOMY; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 67049159650     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20940     Document Type: Article

References (74)

1. Bartsch W, Klein H, Schiemann U, Bauer HW, Voigt KD. Enzymes of androgen formation and degradation in the human prostate. Ann NY Acad Sci 1990;595:53-66. (Pubitemid 20282939)
2. Miller WL, Auchus RJ, Geller DH. The regulation of 17,20 lyase activity. Steroids 1997;62:133-142. (Pubitemid 27066997)
3. Pandey AV, Miller WL. Regulation of 17,20 lyase activity by cytochrome b5 and by serine phosphorylation of P450c17. J Biol Chem 2005;280:13265-13271. (Pubitemid 40517210)
4. Dharia S, Slane A, Jian M, Conner M, Conley AJ, Parker CR Jr. Colocalization of P450c17 and cytochrome b5 in androgen-synthesizing tissues of the human. Biol Reprod 2004;71:83-88. (Pubitemid 38915312)
5. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004;25:947-970. (Pubitemid 39657774)
6. Akhtar MK, Kelly SL, Kaderbhai MA. Cytochrome b(5) modulation of 17{alpha} hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis. J Endocrinol 2005;187:267-274.
7. Tagashira H, Kominami S, Takemori S. Kinetic studies of cytochrome P-45017 alpha, lyase dependent androstenedione formation from progesterone. Biochemistry 1995;34:10939-10945.
8. Gupta MK, Guryev OL, Auchus RJ. 5alpha-reduced C21 steroids are substrates for human cytochrome P450c17. Arch Biochem Biophys 2003;418:151-160. (Pubitemid 37159381)
9. Auchus RJ, Worthy K, Geller DH, Miller WL. Probing structural and functional domains of human P450c17. Endocr Res 2000;26:695-703. (Pubitemid 32053092)
10. Mathieu AP, Auchus RJ, LeHoux JG. Comparison of the hamster and humanadrenal P450c17 (17 alpha-hydroxylase/17,20-lyase) using site-directed mutagenesis and molecular modeling. J Steroid Biochem Mol Biol 2002;80:99-107. (Pubitemid 34178416)
11. Auchus RJ, Miller WL. Molecular modeling of human P450c17 (17alpha-hydroxylase/17,20-lyase): Insights into reaction mechanisms and effects of mutations. Mol Endocrinol 1999;13:1169-1182. (Pubitemid 30644304)
12. Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004;15:432-438. (Pubitemid 39440726)
13. Bhangoo A, Aisenberg J, Chartoffe A, Ten S, Wallerstein RJ, Wolf R, Auchus RJ. Novel mutation in cytochrome P450c17 causes complete combined 17alpha-hydroxylase/17,20-lyase deficiency. J Pediatr Endocrinol Metab 2008;21:185-190.
14. Rosenfield RL, Barnes RB, Ehrmann DA. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1994;79:1686-1692.
15. Ghayee HK, Auchus RJ. Basic concepts and recent developments in human steroid hormone biosynthesis. Rev Endocr Metab Disord 2007;8:289-300.
16. Park JM, Lee EJ, Ramakrishna S, Cha DH, Baek KH. Association study for single nucleotide polymorphisms in the CYP17A1 gene and polycystic ovary syndrome. Int J Mol Med 2008;22:249-254.
17. Onen IH, Ekmekci A, Eroglu M, Polat F, Biri H. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol 2007;26:100-107. (Pubitemid 46363875)
18. Kakinuma H, Tsuchiya N, Habuchi T, Ohyama C, Matsuura S, Wang L, Nakamura A, Kato T. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5 A2: Implication for prostate cancer risk. Prostate Cancer Prostatic Dis 2004;7:333-337. (Pubitemid 41721792)
19. Madigan MP, Gao YT, Deng J, Pfeiffer RM, Chang BL, Zheng S, Meyers DA, Stanczyk FZ, Xu J, Hsing AW. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: A population-based study in China. Int J Cancer 2003;107:271-275. (Pubitemid 37152909)
20. Stigliano A, Gandini O, Cerquetti L, Gazzaniga P, Misiti S, Monti S, Gradilone A, Falasca P, Poggi M, Brunetti E, Agliano AM, Toscano V. Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol 2007;194:55-61. (Pubitemid 47162887)
21. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-4454.
22. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407-6415.
23. Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: Mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 2008;22:243-258. (Pubitemid 351611949)
24. Ayub M, Levell MJ. Inhibition of human adrenal steroidogenic enzymes in vitro by imidazole drugs including ketoconazole. J Steroid Biochem 1989;32:515-524. (Pubitemid 19135503)
25. Rajfer J, Sikka SC, Rivera F, Handelsman DJ. Mechanism of inhibition of human testicular steroidogenesis by oral ketoconazole. J Clin Endocrinol Metab 1986;63:1193-1198. (Pubitemid 17173060)
26. Madan RA, Arlen PM. Abiraterone. Cougar biotechnology. IDrugs 2006;9:49-55.
27. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase, I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-4571.
28. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients:Aphase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-1033. (Pubitemid 41095034)
29. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997;157:1204-1207. (Pubitemid 27130781)
30. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005;96:1241-1246. (Pubitemid 41743917)
31. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 2005;92:305-311. (Pubitemid 40343146)
32. Lancaster GI, Febbraio MA. Exosome-dependent trafficking of HSP70: A novel secretory pathway for cellular stress proteins. J Biol Chem 2005;280:23349-23355. (Pubitemid 40853248)
33. Johnstone RM. Revisiting the road to the discovery of exosomes. Blood Cells Mol Dis 2005;34:214-219. (Pubitemid 40693557)
34. Yu X, Harris SL, Levine AJ. The regulation of exosome secretion: A novel function of the p53 protein. Cancer Res 2006;66:4795-4801.
35. Hales DB, Sha LL, Payne AH. Testosterone inhibits cAMP-induced de Novo synthesis of Leydig cell cytochrome P-450(17 alpha) by an androgen receptor-mediated mechanism. J Biol Chem 1987;262:11200-11206.
36. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004;59:337-349. (Pubitemid 38509767)
37. Fedoruk Matthew N, Gimenez-Bonafe P, Guns Emma S, Mayer Lawrence D, Nelson Colleen C. P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate 2004;59:77-90. (Pubitemid 38387845)
38. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891-2898. (Pubitemid 29493968)
39. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004;64:6595-6602. (Pubitemid 39297919)
40. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005;65:11083-11093. (Pubitemid 41713379)
41. Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 2004;22:179-184. (Pubitemid 39377910)
42. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-285. (Pubitemid 29124362)
43. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000;141:2257-2265. (Pubitemid 32274381)
44. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005;23:1-9. (Pubitemid 40425164)
45. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-448. (Pubitemid 38173980)
46. Van der Kwast V, Schalken TH, Ruizevend J, de Winter JA. Androgen receptors in endocrine therapy-resistant human prostate cancer. Int J Cancer 1991;48:189-193.
47. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi O. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-406.
48. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-319. (Pubitemid 27036612)
49. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-2898. (Pubitemid 32691931)
50. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-4657. (Pubitemid 41557182)
51. Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med 2004;22:299-309. (Pubitemid 40030080)
52. Suzuki K, Nishiyama T, Hara N, Yamana K, Takahashi K, Labrie F. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis 2007;10:301-306. (Pubitemid 47351410)
53. Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006;95:767-774. (Pubitemid 44498089)
54. Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008;8:449-457.
55. Heemers HV, VerhoevenG, Swinnen JV. Androgen activation of the sterol regulatory element-binding protein pathway: Current insights. Mol Endocrinol 2006;20:2265-2277. (Pubitemid 44496400)
56. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004;64:2212-2221. (Pubitemid 38339475)
57. Ozbay T, Rowan A, Leon A, Patel P, Sewer MB. Cyclic adenosine 5′-monophosphate-dependent sphingosine-1-phosphate biosynthesis induces human CYP17 gene transcription by activating cleavage of sterol regulatory element binding protein 1. Endocrinology 2006;147:1427-1437. (Pubitemid 43244377)
58. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26:263-273.
59. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgenin-dependent prostate cancer. Cancer Res 2006;66:2815-2825.
60. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS. Intraprostatic androgens and androgenregulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033-5041. (Pubitemid 46910214)
61. Shen MM, Abate-Shen C. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res 2007;67:6535-6538.
62. Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 2007;7:591-604. (Pubitemid 47358145)
63. Ghosh PM, Malik S, Bedolla R, Kreisberg JI. Akt in prostate cancer: Possible role in androgen-independence. Curr Drug Metab 2003;4:487-496. (Pubitemid 37536869)
64. Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007;102:1368-1374.
65. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008;7:1745-1762. (Pubitemid 351988740)
66. Lespagnol A, Duflaut D, Beekman C, Blanc L, Fiucci G, Marine JC, Vidal M, Amson R, Telerman A. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ 2008;15:1723-1733.
67. Schorey JS, Bhatnagar S. Exosome function: From tumor immunology to pathogen biology. Traffic 2008;9:871-881. (Pubitemid 351639493)
68. van Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: A common pathway for a specialized function. J Biochem 2006;140:13-21. (Pubitemid 44433541)
69. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-659. (Pubitemid 47214727)
70. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008;15:80-88. (Pubitemid 350286175)
71. Fevrier B, Raposo G. Exosomes: Endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 2004;16:415-421. (Pubitemid 38903148)
72. Hegmans JP, Bard MP, Hemmes A, Luider TM, Kleijmeer MJ, Prins JB, Zitvogel L, Burgers SA, Hoogsteden HC, Lambrecht BN. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol 2004;164:1807-1815. (Pubitemid 38529783)
73. Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, Terrian DM. Senescence-associated exosome release from human prostate cancer cells. Cancer Res 2008;68:7864-7871.
74. Paterson RF, Gleave ME, Jones EC, Zubovits JT, Goldenberg SL, Sullivan LD. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormonal therapy. Mol Urol 1999;3:277-286. (Pubitemid 29511047)